Excretion connection VMA-99-82 — a novel adenine having antiviral activity
Abstract
In the study of excretion of the drug established that VMA-99-82 detected in the urine for at least 72 hours of the study. Renal clearance was 0.936 ml/hr, extrarenal — 666.04 ml/h by intravenous route of administration, 1.8 ml/hr and 1009.72 ml/h, respectively, by the oral route of administration. Superiority over the renal clearance extrarenal correlates with earlier data on the distribution of the compound VMA-99-82 in organs and tissues. The drug was determined in the kidney in low concentrations and by intravenous and oral routes of administration. Tissue availability was 0,452 and 0,413 in intravenous and oral routes of administration, respectively. Win unmodified substance elimination of the administered dose is less than 1%, and its amount in the feces is about 5 times lower than that in the urine. In this regard, we can assume an intense flow of processes of biotransformation.
Conflicts of Interest Disclosure:
The authors declares that there is no conflict of interest.
Article info:
Date submitted: 09.04.2020
All authors have read and approved the final manuscript.
Peer review info:
"Pharmacokinetics and Pharmacodynamics" thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Editorial comment:
In case of any discrepancies in a text or the differences in its layout between the pdf-version of an article and its html-version the priority is given to the pdf-version.
About the Authors
L. A. Smirnova
Institute of Pharmacology, Volgograd Medical University
Russian Federation
E. A. Suchkov
Institute of Pharmacology, Volgograd Medical University
Russian Federation
A. F. Ryabukha
Institute of Pharmacology, Volgograd Medical University
Russian Federation
K. A. Kuznetsov
Institute of Pharmacology, Volgograd Medical University
Russian Federation
A. A. Ozerov
Institute of Pharmacology, Volgograd Medical University
Russian Federation
A. V. Karavaev
Institute of Pharmacology, Volgograd Medical University
Russian Federation
References
1. Белоусов. Ю.Б. Клиническая фармакокинетика, Москва, Литтерра. 2005.
2. Каркищенко Н.Н., Хоронько В.В., Сергеева С.А., Каркищенко В.Н. Фармакокинетика, Ростов-на-Дону, Феникс. 2001.
3. Петров В.И., Озеров А.А., Новиков М.С.и др. Фундаментальные исследования. 2004. № 1. С. 78-79
4. Петров В.И., Озеров А.А., Новиков М.С. и др. Вестник Волгоградского государственного медицинского университета, 2004. № 11. С.21-24
5. Petrov V.I., Ozerov A.A., Novikov M.S. Chemistry of Heterocyclic Compounds, 2003. Vol. 39 (9). P. 1218-1226.
6. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. // Р.У. Хабриев (ред.), Москва. 2005.
7. Дерфель К. Статистика в аналитической химии. Москва, Мир. 1994.
For citations:
Smirnova L.A.,
Suchkov E.A.,
Ryabukha A.F.,
Kuznetsov K.A.,
Ozerov A.A.,
Karavaev A.V.
Excretion connection VMA-99-82 — a novel adenine having antiviral activity. Pharmacokinetics and Pharmacodynamics. 2013;(1):40-42.
(In Russ.)
Views:
419